<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00565240</url>
  </required_header>
  <id_info>
    <org_study_id>WHIRL-07-59</org_study_id>
    <nct_id>NCT00565240</nct_id>
  </id_info>
  <brief_title>Mid-luteal Phase Synchronization of Ovarian Folliculogenesis in Women</brief_title>
  <official_title>Mid-luteal Phase Synchronization of Ovarian Folliculogenesis in Women Protocol: WHIRL-07-2971</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Saskatchewan</source>
  <brief_summary>
    <textblock>
      We hypothesize that administration of an aromatase inhibitor (AI) and hormonal contraceptives
      (HC) in the mid-luteal phase of the menstrual cycle will result in atresia of the follicles
      in the extant wave and cause synchronous re-emergence of a new follicular wave. We anticipate
      that this will provide us with information to facilitate the development of a new method for
      ovarian synchronization; a safer, more effective ovulation induction therapy; a new method
      for emergency contraception; and a greater understanding of human folliculogenesis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate differences in the mechanisms of atresia, initiation of a new synchronous follicular wave, interval to follicle wave emergence, interval to emergence of dominant follicle, interval to menstruation, and endometrial thickness/pattern.</measure>
    <time_frame>24-28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate between treatment group differences in ultrasonographic image attributes of follicular structures that develop after administration of treatment.</measure>
    <time_frame>ongoing</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Ovarian Follicle</condition>
  <arm_group>
    <arm_group_label>Oral Contraceptive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Contraceptive Ring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aromatase Inhibitors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Marvelon</intervention_name>
    <description>oral contraceptive</description>
    <arm_group_label>Oral Contraceptive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nuvaring</intervention_name>
    <description>contraceptive vaginal ring</description>
    <arm_group_label>Contraceptive Ring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Aromatase Inhibitors</description>
    <arm_group_label>Aromatase Inhibitors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. female volunteers of childbearing potential;

          2. are first time users of OC or have discontinued OC at least 2 months prior to study
             entry;

          3. age between 18 and 35 years old;

          4. normal body mass index (18-30);

          5. has signed consent form; and

          6. is in good health as confirmed by medical history, physical examination

        Exclusion Criteria:

          1. a positive pregnancy test will automatically exclude the volunteer from participation
             in this study.

          2. any contraindication for oral contraception use;

          3. known hypersensitivity to Letrozole and co-administered medications;

          4. irregular menstrual cycles;

          5. ultrasonographic evidence of ovarian dysfunction, such as Polycystic Ovary Syndrome
             (PCOS);

          6. history of pituitary tumor;

          7. HIV, HBV, HCV infection;

          8. vaginal infection;

          9. abnormal ECG;

         10. abnormal lab tests for blood profile, liver function and renal function;

         11. uncontrolled diabetes and blood pressure;

         12. pregnancy (suspected or diagnosed) or lactation;

         13. history or suspicion of drug or alcohol abuse;

         14. history of severe mental disorders;

         15. participation in an investigational drug trial within the 30 days prior to selection;

         16. exhibits a disorder that is a contraindication to steroid hormonal therapy, including,
             for example, the following conditions:

               -  history of, or actual, thrombophlebitis or thromboembolic disorders.

               -  history of, or actual, cerebrovascular disorders.

               -  history of, or actual, myocardial infarction or coronary artery disease.

               -  acute liver disease.

               -  history of, or actual, benign or malignant liver tumors.

               -  history of, or suspected, carcinoma of the breast.

               -  known, or suspected, estrogen-dependent neoplasia.

               -  undiagnosed abnormal vaginal bleeding.

               -  any ocular lesion arising from ophthalmic vascular disease, such as partial or
                  complete loss of vision or defect in visual field.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger A Pierson</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2007</study_first_submitted>
  <study_first_submitted_qc>November 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2007</study_first_posted>
  <last_update_submitted>April 20, 2010</last_update_submitted>
  <last_update_submitted_qc>April 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Roger Pierson</name_title>
    <organization>University of Saskatchewan</organization>
  </responsible_party>
  <keyword>ovarian synchronization</keyword>
  <keyword>folliculogenesis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Desogestrel</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

